Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Seer Inc Cl A
(NQ:
SEER
)
2.380
+0.090 (+3.93%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
186,478
Open
2.300
Bid (Size)
2.300 (10)
Ask (Size)
2.390 (4)
Prev. Close
2.290
Today's Range
2.300 - 2.429
52wk Range
1.510 - 2.500
Shares Outstanding
65,088,575
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 21, 2024
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in Upcoming November Investor Conferences
November 08, 2024
From
Seer, Inc.
Via
GlobeNewswire
Performance
YTD
+22.68%
+22.68%
1 Month
+27.96%
+27.96%
3 Month
+46.91%
+46.91%
6 Month
+20.20%
+20.20%
1 Year
+45.12%
+45.12%
More News
Read More
Seer Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Seer, Inc.
Via
GlobeNewswire
Recap: Seer Q4 Earnings
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
November 06, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
October 31, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
October 21, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
October 17, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Appoints Nicolas Roelofs to its Board of Directors
August 14, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 09, 2024
From
Seer, Inc.
Via
GlobeNewswire
SEER Stock Earnings: Seer Beats EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Seer Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
June 11, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
June 02, 2024
From
Seer, Inc.
Via
GlobeNewswire
SEER Stock Earnings: Seer Meets EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Seer Reports First Quarter 2024 Financial Results
May 08, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
May 08, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
April 23, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
February 29, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
February 21, 2024
From
Seer, Inc.
Via
GlobeNewswire
Zoom Video And 2 Other Stocks Insiders Are Selling
February 08, 2024
Via
Benzinga
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
February 06, 2024
From
Seer, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.